SCHEMBL829543

SCHEMBL829543

CN1CCN(C(=O)Oc2cc(Cl)c(Cl)cc2Cl)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KMT2A Q03164 4/20 0.45
HPGD P15428 2/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45
DUSP3 P51452 1/20 0.45
PTPN11 Q06124 1/20 0.45
TSHR P16473 2/20 0.44
HSP90AA1 P07900 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR1D P28221 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL828934 0.85 MAPT (0.55) MAPTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL830223 0.83 TDP1 (0.57) MAPTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL829898 0.81 GAA (0.54) MAPTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL829425 0.78 FAAH (0.56) MAPTSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL829523 0.77 HRH4 (0.48) MAPTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL13342918 0.76 CYP1A2 (0.62) MAPTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL22372598 0.76 EGFR (0.40) MAPTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL830773 0.75 LMNA (0.43) KMT2AHPGDMEN1ALDH1A1LMNA
SCHEMBL22372611 0.75 USP30 (0.56) MAPTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL28834161 0.75 TSHR (0.52) MAPTSMN1; SMN2KMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 MAPT 3311/4885SMN1; SMN2 4842/4885KMT2A 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.